Thuy B Tran1, David J Worhunsky1, Malcolm H Squires2, Linda X Jin3, Gaya Spolverato4, Konstantinos I Votanopoulos5, Clifford S Cho6, Sharon M Weber6, Carl Schmidt7, Edward A Levine5, Mark Bloomston7, Ryan C Fields3, Timothy M Pawlik4, Shishir K Maithel2, Jeffrey A Norton1, George A Poultsides8. 1. Department of Surgery, Stanford Cancer Institute, Stanford University, 300 Pasteur Drive, Suite H3680D, Stanford, CA, 94305, USA. 2. Department of Surgery, Winship Cancer Institute, Emory University, Atlanta, GA, USA. 3. Department of Surgery, Barnes-Jewish Hospital and Alvin J. Siteman Cancer Center, Washington University, St Louis, MO, USA. 4. Department of Surgery, Johns Hopkins University, Baltimore, MD, USA. 5. Department of Surgery, Wake Forest University, Winston-Salem, NC, USA. 6. Department of Surgery, University of Wisconsin, Madison, WI, USA. 7. Department of Surgery, Ohio State University, Columbus, OH, USA. 8. Department of Surgery, Stanford Cancer Institute, Stanford University, 300 Pasteur Drive, Suite H3680D, Stanford, CA, 94305, USA. gpoultsides@stanford.edu.
Abstract
BACKGROUND: Although the extent of resection frequently dictates the method of reconstruction following distal subtotal gastrectomy, it is unclear whether Roux-en-Y gastrojejunostomy compared with Billroth II gastrojejunostomy is associated with superior perioperative outcomes. METHODS: Patients who underwent resection for gastric cancer with Roux-en-Y or Billroth II reconstruction between 2000 and 2012 in seven academic institutions (US Gastric Cancer Collaborative) were identified. Patients who underwent total gastrectomy, gastric wedge, or palliative resections (metastatic disease or R2 resections) were excluded. RESULTS: Of a total of 965 patients, 447 met the inclusion criteria. A comparison between the Roux-en-Y (n = 257) and Billroth II (n = 190) groups demonstrated no differences in patient and tumor characteristics, except for Billroth II patients having a higher proportion of antral tumors (71 % vs. 50 %, p < 0.001). Roux-en-Y operations were slightly longer (244 min vs. 212 min, p < 0.001) and associated with somewhat higher blood loss (243 ml vs. 205 ml, p = 0.033). However, there were no significant differences in the length of hospital stay (8 days vs. 7 days), readmission rate (17 % vs. 18 %), 90-day mortality (5.1 % vs. 4.7 %), incidence (39 % vs. 41 %) and severity of complications, dependency on jejunostomy tube feeding at discharge (13 % vs. 12 %), same-patient decrease in serum albumin level from the preoperative to the postoperative value at 30, 60, and 90 days, receipt of adjuvant therapy (50 % vs. 53 %), or 5-year survival (44 % vs. 41 %). CONCLUSIONS: Although long-term quality-of-life parameters were not compared, this study did not show an advantage of Roux-en-Y gastrojejunostomy over Billroth II gastrojejunostomy in short-term perioperative outcomes. Both techniques should be regarded as equally acceptable reconstructive options following partial gastrectomy for gastric cancer.
BACKGROUND: Although the extent of resection frequently dictates the method of reconstruction following distal subtotal gastrectomy, it is unclear whether Roux-en-Y gastrojejunostomy compared with Billroth II gastrojejunostomy is associated with superior perioperative outcomes. METHODS:Patients who underwent resection for gastric cancer with Roux-en-Y or Billroth II reconstruction between 2000 and 2012 in seven academic institutions (US Gastric Cancer Collaborative) were identified. Patients who underwent total gastrectomy, gastric wedge, or palliative resections (metastatic disease or R2 resections) were excluded. RESULTS: Of a total of 965 patients, 447 met the inclusion criteria. A comparison between the Roux-en-Y (n = 257) and Billroth II (n = 190) groups demonstrated no differences in patient and tumor characteristics, except for Billroth II patients having a higher proportion of antral tumors (71 % vs. 50 %, p < 0.001). Roux-en-Y operations were slightly longer (244 min vs. 212 min, p < 0.001) and associated with somewhat higher blood loss (243 ml vs. 205 ml, p = 0.033). However, there were no significant differences in the length of hospital stay (8 days vs. 7 days), readmission rate (17 % vs. 18 %), 90-day mortality (5.1 % vs. 4.7 %), incidence (39 % vs. 41 %) and severity of complications, dependency on jejunostomy tube feeding at discharge (13 % vs. 12 %), same-patient decrease in serum albumin level from the preoperative to the postoperative value at 30, 60, and 90 days, receipt of adjuvant therapy (50 % vs. 53 %), or 5-year survival (44 % vs. 41 %). CONCLUSIONS: Although long-term quality-of-life parameters were not compared, this study did not show an advantage of Roux-en-Y gastrojejunostomy over Billroth II gastrojejunostomy in short-term perioperative outcomes. Both techniques should be regarded as equally acceptable reconstructive options following partial gastrectomy for gastric cancer.
Authors: Jacques Ferlay; Hai-Rim Shin; Freddie Bray; David Forman; Colin Mathers; Donald Maxwell Parkin Journal: Int J Cancer Date: 2010-12-15 Impact factor: 7.396
Authors: Stephen R Grobmyer; Scott T Hollenbeck; David P Jaques; William R Jarnagin; Ronald DeMatteo; Daniel G Coit; Leslie H Blumgart; Murray F Brennan; Yuman Fong Journal: Arch Surg Date: 2008-12
Authors: Jun-Jie Xiong; Kiran Altaf; Muhammad A Javed; Quentin M Nunes; Wei Huang; Gang Mai; Chun-Lu Tan; Rajarshi Mukherjee; Robert Sutton; Wei-Ming Hu; Xu-Bao Liu Journal: World J Gastroenterol Date: 2013-02-21 Impact factor: 5.742
Authors: Mario Musella; Antonio Susa; Emilio Manno; Maurizio De Luca; Francesco Greco; Marco Raffaelli; Stefano Cristiano; Marco Milone; Paolo Bianco; Antonio Vilardi; Ivana Damiano; Gianni Segato; Laura Pedretti; Piero Giustacchini; Domenico Fico; Gastone Veroux; Luigi Piazza Journal: Obes Surg Date: 2017-11 Impact factor: 4.129
Authors: Allison N Martin; Deepanjana Das; Florence E Turrentine; Todd W Bauer; Reid B Adams; Victor M Zaydfudim Journal: J Gastrointest Surg Date: 2016-06-30 Impact factor: 3.452